HIV-positive patients in the intensive care unit

To the Editor: We read the retrospective audit by Mkoko and Raine[1] on HIV-positive patients requiring intensive care unit (ICU) admission with great interest. Although we acknowledge that intensive care is a scarce resource in South Africa (SA), and clear guidelines are needed to assist clinicians to allocate resources appropriately, we cannot concur with the authors’ conclusion that ICU care may have to be withheld from HIV patients with higher Acute Physiology and Chronic Health Evaluation II (APACHE II) scores and the need for organ support such as renal replacement therapy and inotropes. The authors also erroneously suggest that this is the first study that has determined the outcomes of HIV-positive adults admitted to an SA ICU.

In a prospective study performed by Balkema et al.[2] in the same city (Cape Town, SA), during the same period and on a similar population, ICU mortality of all HIV patients was 38.9%. ICU mortality was associated with an AIDS-defining diagnosis (odds ratio 7.97, p=0.003). Non-survivors had higher APACHE II scores (25.8 v. 18.6; p=0.001) and lower mean admission CD4+ counts (102.5 v. 225.2 cells/µL; p=0.014). Multiple logistical regression analysis confirmed the independent predictive value of World Health Organization (WHO) stage IV disease (p=0.008), lower mean CD4+ counts on admission (p=0.057), and higher APACHE II scores (p=0.010) on ICU mortality, and of WHO stage IV disease (p=0.007) and higher APACHE II scores (p=0.003) on 30-day mortality. In a post hoc analysis, the same investigators retrospectively validated a simple six-point scoring system based on the presence of: (i) AIDS; (ii) a CD4+ count of <50 cells/µL; (iii) extrapulmonary tuberculosis; (iv) Pneumocystis carinii pneumonia; (v) septic shock; and (vi) renal dysfunction. More than 80% of patients with a score of ≥3 died, and no patient with a score of ≥4 survived.[3]

The ICU mortality in Mkoko and Raine’s study[1] was 25.3% in patients with a mean (standard deviation) APACHE II score of 21.6 (8.4). This would be anticipated, as the predicted mortality with an APACHE II score in the range of 20 - 24, regardless of HIV status, is up to 40%. Moreover, the APACHE II score was designed as an estimate of mortality after 24 hours of ICU care and not as a guide to offer or withhold critical care.[4] The need for inotropic support is also widely regarded as an independent predictor of mortality in HIV-negative ICU patients. The 47% mortality described in the study would therefore also be anticipated and may not be indicative of mortality specifically attributable to HIV infection in this setting.[5]

We therefore cannot concur with the authors’ interpretation to ‘withhold’ ICU care in only the HIV population with these general critical illness severity indices. In the absence of randomised studies or higher levels of evidence, it is still safer to discuss referrals on a case-by-case basis and to consider all comorbidities.

A Parker
Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
aparker@sun.ac.za

S Lahri
Department of Emergency Medicine, Khayelitsha Hospital, Cape Town, South Africa

J J Taljaard
Division of Infectious Diseases, Department of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa

C F N Koegelenberg
Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa


